Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.58 |
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7473622 | 0.83 | CRHR1 (0.58) | CRHR1BRD4TLR7SCN9A | |
| SCHEMBL4627787 | 0.82 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL7119050 | 0.81 | CRHR1 (0.48) | CRHR1TLR7ADORA3 | |
| SCHEMBL6201263 | 0.81 | CRHR1 (0.62) | CRHR1BRD4TLR7SCN9A | |
| SCHEMBL6202450 | 0.80 | CRHR1 (0.56) | CRHR1BRD4TLR7 | |
| SCHEMBL6201786 | 0.80 | CRHR1 (0.60) | CRHR1BRD4SCN9A | |
| SCHEMBL7476681 | 0.80 | CRHR1 (0.58) | CRHR1BRD4SCN9AADORA3 | |
| SCHEMBL6203614 | 0.79 | CRHR1 (0.70) | CRHR1BRD4SCN9A | |
| SCHEMBL7472049 | 0.78 | CRHR1 (0.56) | CRHR1TLR7ADORA3 | |
| SCHEMBL7477682 | 0.77 | CRHR1 (0.57) | CRHR1BRD4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | CRHR1 1/4885BRD4 1399/4885TLR7 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.